At a stage when drug-resistant hypertension is re-emerging potently our results can also provide a background for developing trials on the clinical use of urotensin II receptor antagonists that should consider the effects of urotensin II on renin and aldosterone, at variance with what done so far. This evidence concerns the gene REN and Hypertension.